Attaya Suvannasankha MD
Hematologic Oncology
Associate Professor, Medicine, Indiana University School of Medicine
Join to View Full Profile
1044 W Walnut St# R4Indianapolis, IN 46202
Phone+1 317-274-0843
Fax+1 317-274-0936
Dr. Suvannasankha is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Education & Training
University at BuffaloFellowship, Hematology and Medical Oncology, 2000 - 2003
Albert Einstein Healthcare NetworkResidency, Internal Medicine, 1997 - 2000
Chulalongkorn University Faculty of MedicineClass of 1996
Certifications & Licensure
IN State Medical License 2003 - 2025
PA State Medical License 1998 - 2000
American Board of Internal Medicine Hematology
Clinical Trials
- Zoledronic Acid in the Management of Patients With Asymptomatic/Early Stage Multiple Myeloma Start of enrollment: 2005 Jun 01
- Phase II Study of Revlimid®, Oral Cyclophosphamide and Prednisone for Patients With Newly Diagnosed Multiple Myeloma Start of enrollment: 2007 Oct 01
- Lenalidomide and High Dose Melphalan Followed by Autologous Stem Cell Transplant in Multiple Myeloma Start of enrollment: 2010 Aug 27
- Join now to see all
Publications & Presentations
PubMed
- The American Federation for Medical Research maintains commitment to decades of support of vaccine and vaccination research to improve public health.Zanthia Wiley, Sidharth Mahapatra, Gaurav Agarwal, Stephanie Baer, Syed Bukhari
Journal of Investigative Medicine. 2025-04-01 - 1 citationsCancer Surveillance in Solid Organ Transplant Recipients With a Pretransplant History of Malignancy: Multidisciplinary Collaborative Expert Opinion.Kymberly D Watt, Stacey Rolak, David P Foley, Jennifer K Plichta, Sandhya Pruthi
Transplantation. 2024-12-01 - 1 citationsSafety and efficacy of belantamab mafodotin with pembrolizumab in patients with relapsed or refractory multiple myeloma.Attaya Suvannasankha, Nizar Bahlis, Suzanne Trudel, Katja Weisel, Christian Koenecke
Cancer. 2024-08-01
Press Mentions
First-in-Human Multiple Myeloma Study Shows 90 Percent Response RateApril 19th, 2023- Early Data Indicates New Therapy Is ‘Safe and Effective’ for Cancer Metastases in BonesApril 29th, 2021
Purdue Researchers at Work on Anemia App to Make Detection EasierNovember 30th, 2017
Professional Memberships
- Member
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence:
